Vemurafenib

In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation.

Uloženo v:

Podrobná bibliografie
Vydáno v:	Nature reviews. Drug discovery Ročník 10; číslo 11; s. 811 - 812
Hlavní autoři:	Flaherty, Keith. T, Yasothan, Uma, Kirkpatrick, Peter
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 01.11.2011 Nature Publishing Group
Témata:	631/154 67 692/699/67/1813/1634 Animals Biomedical and Life Sciences Biomedicine Biotechnology Cancer Cancer Research Care and treatment Clinical trials Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Drug therapy fresh-from-the-pipeline Humans Indoles - pharmacology Indoles - therapeutic use Medicinal Chemistry Melanoma Melanoma - drug therapy Melanoma - enzymology Melanoma - genetics Metastasis Molecular Medicine Pharmacology/Toxicology Physiological aspects Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins B-raf - metabolism Ras genes Sulfonamides - pharmacology Sulfonamides - therapeutic use Vemurafenib
ISSN:	1474-1776, 1474-1784, 1474-1784
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation.
Bibliografie:	SourceType-Scholarly Journals-1 ObjectType-News-1 content type line 14 content type line 23
ISSN:	1474-1776 1474-1784 1474-1784
DOI:	10.1038/nrd3579